ClinicalTrials.gg
CompletedNCT00633932Updated Dec 20, 2010Results posted

Reflux Esophagitis Phase III Study (Initial Treatment)

A Phase 3 interventional study of Esomeprazole and Esomeprazole in Reflux Esophagitis, sponsored by AstraZeneca. Completed at 41 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2010-12-20.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
602
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Esophagitis, Peptic by AstraZeneca — none open to participants now, none under way, none of them phase 3. Esophagitis, Peptic · AstraZeneca.

Started
2007
with 1 other
Phase 3
5 of 12
none open now
Registered
2nd of 12
by date

Among the 12 studies in Esophagitis, Peptic by AstraZeneca, this one is one of 2 that started in 2007, is one of 5 in phase 3, and was the 2nd registered.

Esophagitis, Peptic

83 studies on the registry are indexed under Esophagitis, Peptic; 16 are open to participants now.

Browse Esophagitis, Peptic studies →

Open to participants now

None of the 12 studies in Esophagitis, Peptic by AstraZeneca is open now. The open studies under Esophagitis, Peptic, anywhere →

Where they have run

Who these studies take

Of the 8 Esophagitis, Peptic studies recruiting now, 3 set no upper age limit and 3 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis, Peptic by AstraZeneca as a file.
02

Study summary

This study is to evaluate the efficacy of esomeprazole 20 mg once daily and 40 mg once daily for 8 weeks on healing of Reflux Esophagitis in patients with reflux esophagitis in comparison with omeprazole 20 mg once daily by assessment of presence/absence of Reflux Esophagitis at Week 8 according to the Los Angeles classification .

03

Conditions studied

  • Reflux Esophagitis

Browse trials for

Keywords

  • Reflux Esophagitis
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Endoscopically verified Reflux Esophagitis classified into Los Angeles classification Grade A, B, C or D within 1 week before randomisation

Exclusion criteria

Exclusion Criteria:

  • Gastric or duodenal ulcer verified by EGD within 12 weeks before randomisation.
  • Use of any PPI from 14 days before EGD performed at the screening visit to the day of randomisation.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
602 participants (actual)

Study arms

  • Experimental
    1

    Esomeprazole 20mg

    Drug: Esomeprazole

  • Experimental
    2

    Esomeprazole 40mg

    Drug: Esomeprazole

  • Active comparator
    3

    Omeprazole 20mg

    Drug: Omeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification".

    Los Angeles classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C, Grade D). The subjects who were definitely diagnosed to have RE classified into LA classification Grade A, B, C or D based on the EGD on Visit 1 were randomised. A subject classified into LA classification Grade O was considered no reflux esophagitis. The definitions of each grade are: Grade A (Mucosal break \< 5 mm in length), Grade B (Mucosal break \> 5mm), Grade C (Mucosal break continuous between \> 2 mucosal folds) and Grade D (Mucosal break \>75% of esophageal circumference).

    Time frame: 8 weeks

Secondary outcomes

  1. Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 4 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification

    Los Angeles classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). The subjects who were definitely diagnosed to have RE classified into LA classification Grade A, B, C or D based on the EGD on Visit 1 were randomised. A subject classified into LA classification Grade O was considered no reflux esophagitis. The definitions of each grade are: Grade A (Mucosal break \< 5 mm in length), Grade B (Mucosal break \> 5mm), Grade C (Mucosal break continuous between \> 2 mucosal folds) and Grade D (Mucosal break \>75% of esophageal circumference).

    Time frame: 4 weeks

07

Results

Posted Apr 8, 2010

Participant flow

First subject enrolled on 11 December 2007. Last subject completed on 12 December 2008.

Participant flow — Overall Study
MilestoneExperimental: Esomeprazole 40mgExperimental: Esomeprazole 20mgComparator: Omeprazole 20mg
Started191190191
Completed179176180
Not completed121411
Withdrew: Adverse event134
Withdrew: Withdrawal by subject391
Withdrew: Lost to follow-up102
Withdrew: Protocol violation523
Withdrew: Physician decision001
Withdrew: Doctor's judgement100
Withdrew: Moved away100

Outcome measures

PrimaryNumber of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification".

Los Angeles classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C, Grade D). The subjects who were definitely diagnosed to have RE classified into LA classification Grade A, B, C or D based on the EGD on Visit 1 were randomised. A subject classified into LA classification Grade O was considered no reflux esophagitis. The definitions of each grade are: Grade A (Mucosal break \< 5 mm in length), Grade B (Mucosal break \> 5mm), Grade C (Mucosal break continuous between \> 2 mucosal folds) and Grade D (Mucosal break \>75% of esophageal circumference).

Time frame:
8 weeks
Reported as:
Number · participants
Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification".
participantsExperimental: Esomeprazole 40mgExperimental: Esomeprazole 20mgComparator: Omeprazole 20mg
Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 8 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification".171165166
SecondaryNumber of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 4 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification

Los Angeles classification consists of 5 grades (Grade O, Grade A, Grade B, Grade C and Grade D). The subjects who were definitely diagnosed to have RE classified into LA classification Grade A, B, C or D based on the EGD on Visit 1 were randomised. A subject classified into LA classification Grade O was considered no reflux esophagitis. The definitions of each grade are: Grade A (Mucosal break \< 5 mm in length), Grade B (Mucosal break \> 5mm), Grade C (Mucosal break continuous between \> 2 mucosal folds) and Grade D (Mucosal break \>75% of esophageal circumference).

Time frame:
4 weeks
Reported as:
Number · participants
Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 4 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification
participantsExperimental: Esomeprazole 40mgExperimental: Esomeprazole 20mgComparator: Omeprazole 20mg
Number of Participants With Healing of Reflux Esophagitis (RE) Who Were Graded "O" at Week 4 Out of Patients Who Were Graded "A, B, C or D" at Baseline According to Los Angeles Classification141147143

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Esomeprazole 40mg—0/190 (0%)12/190 (6.3%)
Experimental: Esomeprazole 20mg—1/189 (0.5%)9/189 (4.8%)
Comparator: Omeprazole 20mg—1/190 (0.5%)16/190 (8.4%)
Most frequent serious events
Most frequent serious events
EventExperimental: Esomeprazole 40mgExperimental: Esomeprazole 20mgComparator: Omeprazole 20mg
BronchopneumoniaInfections and infestations0/1901/1890/190
Influenza Like IllnessGeneral disorders0/1901/1890/190
GastroenteritisInfections and infestations0/1900/1891/190
Most frequent other events
Most frequent other events
EventExperimental: Esomeprazole 40mgExperimental: Esomeprazole 20mgComparator: Omeprazole 20mg
NasopharyngitisInfections and infestations10/1906/18910/190
DiarrhoeaGastrointestinal disorders2/1903/1896/190

Baseline characteristics

Age, Customized
Age, Customized(Participants)Experimental: Esomeprazole 40mgExperimental: Esomeprazole 20mgComparator: Omeprazole 20mgTotal
< 65 years127135126388
65 - 74 years473644127
>= 75 years16182054
Missing1113
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Experimental: Esomeprazole 40mgExperimental: Esomeprazole 20mgComparator: Omeprazole 20mgTotal
Male139137134410
Female515256159
Missing1113
08

Study locations

41 sites
  • Research Site
    Kashiwa, Chiba, Japan
  • Research Site
    Kisarazu, Chiba, Japan
  • Research Site
    Koriyama, Fukishima, Japan
  • Research Site
    Nihonmatsu, Fukishima, Japan
  • Research Site
    Nishishirakawa, Fukishima, Japan
  • Research Site
    Kurume, Fukuoka, Japan
  • Research Site
    Nukaya, Fukuoka, Japan
  • Research Site
    Shirakawa, Fukushima, Japan
  • Research Site
    Sugawa, Fukushima, Japan
  • Research Site
    Gifu-shi, Gifu, Japan
  • Research Site
    Maebashi, Gunma, Japan
  • Research Site
    Yasunaka, Gunma, Japan
  • Research Site
    Sapporo, Hokkaido, Japan
  • Research Site
    Hitachi, Ibaraki, Japan
  • Research Site
    Mito, Ibaraki, Japan
  • Research Site
    Tsukuba, Ibaraki, Japan
  • Research Site
    Sakaide, Kagawa, Japan
  • Research Site
    Takamatsu, Kagawa, Japan
  • Research Site
    Fujisawa, Kanagawa, Japan
  • Research Site
    Kawasaki, Kanagawa, Japan
  • Research Site
    Sagamihara, Kanagawa, Japan
  • Research Site
    Yokohama, Kanagawa, Japan
  • Research Site
    Shibata, Myagi, Japan
  • Research Site
    Kiso, Nagano, Japan
  • Research Site
    Matsumoto, Nagano, Japan
  • Research Site
    Fujiidera, Osaka, Japan
  • Research Site
    Toyonaka, Osaka, Japan
  • Research Site
    Ohtawara, Tochigi, Japan
  • Research Site
    Toshima-ku, Tokayo, Japan
  • Research Site
    Adachi, Tokyo, Japan
  • Research Site
    Hachioji, Tokyo, Japan
  • Research Site
    Kiyose, Tokyo, Japan
  • Research Site
    Setagaya, Tokyo, Japan
  • Research Site
    Shinagawa, Tokyo, Japan
  • Research Site
    Shimonoseki, Yamaguchi, Japan
  • Research Site
    Akita, Japan
  • Research Site
    Fukuoka, Japan
  • Research Site
    Kyoto, Japan
  • Research Site
    Oita, Japan
  • Research Site
    Shizuoka, Japan
  • Research Site
    Tottori, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2008
First posted
Mar 12, 2008
Start
Dec 2007
CompletionActual
Dec 2008
Results first posted
Apr 8, 2010
Last update
Dec 20, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00633932
Lead sponsor
AstraZeneca
First posted
Mar 12, 2008
Start date
Dec 2007
Completion
Dec 2008
Results posted
Apr 8, 2010
Last update
Dec 20, 2010

Study contacts

Maotsugu Oyama, MD, PhD
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion